http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 03 Aug 2026 07:05:15 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Biocon+launches+Yesafili%2C+a+biosimilar+to+Eylea+2+mg%2C+in+the+U.S./26853770.html <p>Biocon Limited (BSE: 532523; NSE: BIOCON) has begun the commercial sale of Yesafili (aflibercept-jbvf) in the United States, a biosimilar to Regeneron's Eylea (aflibercept) 2 mg used to treat several ophthalmology conditions.</p> <p>The U.S. Food and Drug Administration approved Yesafili in May 2024 and granted it interchangeable designation for the vial formulation, allowing pharmacy-level substitution in accordance with state laws. The pre-filled syringe carries provisional interchangeability status.</p> <p>Yesafili is indicated for neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. The FDA approval was based on analytical, nonclinical, and clinical data, including a Phase 3 http://www.streetinsider.com/Corporate+News/Biocon+launches+Yesafili%2C+a+biosimilar+to+Eylea+2+mg%2C+in+the+U.S./26853770.html Mon, 03 Aug 2026 07:05:15 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Corporate+News/Biocon+launches+Yesafili%2C+a+biosimilar+to+Eylea+2+mg%2C+in+the+U.S./26853770.html <p>Biocon Limited (BSE: 532523; NSE: BIOCON) has begun the commercial sale of Yesafili (aflibercept-jbvf) in the United States, a biosimilar to Regeneron's Eylea (aflibercept) 2 mg used to treat several ophthalmology conditions.</p> <p>The U.S. Food and Drug Administration approved Yesafili in May 2024 and granted it interchangeable designation for the vial formulation, allowing pharmacy-level substitution in accordance with state laws. The pre-filled syringe carries provisional interchangeability status.</p> <p>Yesafili is indicated for neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. The FDA approval was based on analytical, nonclinical, and clinical data, including a Phase 3 http://www.streetinsider.com/Corporate+News/Biocon+launches+Yesafili%2C+a+biosimilar+to+Eylea+2+mg%2C+in+the+U.S./26853770.html Mon, 03 Aug 2026 07:05:15 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Corporate+News/Biocon+launches+Yesafili%2C+a+biosimilar+to+Eylea+2+mg%2C+in+the+U.S./26853770.html <p>Biocon Limited (BSE: 532523; NSE: BIOCON) has begun the commercial sale of Yesafili (aflibercept-jbvf) in the United States, a biosimilar to Regeneron's Eylea (aflibercept) 2 mg used to treat several ophthalmology conditions.</p> <p>The U.S. Food and Drug Administration approved Yesafili in May 2024 and granted it interchangeable designation for the vial formulation, allowing pharmacy-level substitution in accordance with state laws. The pre-filled syringe carries provisional interchangeability status.</p> <p>Yesafili is indicated for neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. The FDA approval was based on analytical, nonclinical, and clinical data, including a Phase 3 http://www.streetinsider.com/Corporate+News/Biocon+launches+Yesafili%2C+a+biosimilar+to+Eylea+2+mg%2C+in+the+U.S./26853770.html Mon, 03 Aug 2026 07:05:15 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Corporate+News/Biocon+launches+Yesafili%2C+a+biosimilar+to+Eylea+2+mg%2C+in+the+U.S./26853770.html <p>Biocon Limited (BSE: 532523; NSE: BIOCON) has begun the commercial sale of Yesafili (aflibercept-jbvf) in the United States, a biosimilar to Regeneron's Eylea (aflibercept) 2 mg used to treat several ophthalmology conditions.</p> <p>The U.S. Food and Drug Administration approved Yesafili in May 2024 and granted it interchangeable designation for the vial formulation, allowing pharmacy-level substitution in accordance with state laws. The pre-filled syringe carries provisional interchangeability status.</p> <p>Yesafili is indicated for neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. The FDA approval was based on analytical, nonclinical, and clinical data, including a Phase 3 http://www.streetinsider.com/Corporate+News/Biocon+launches+Yesafili%2C+a+biosimilar+to+Eylea+2+mg%2C+in+the+U.S./26853770.html Mon, 03 Aug 2026 07:05:15 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Corporate+News/Biocon+launches+Yesafili%2C+a+biosimilar+to+Eylea+2+mg%2C+in+the+U.S./26853770.html <p>Biocon Limited (BSE: 532523; NSE: BIOCON) has begun the commercial sale of Yesafili (aflibercept-jbvf) in the United States, a biosimilar to Regeneron's Eylea (aflibercept) 2 mg used to treat several ophthalmology conditions.</p> <p>The U.S. Food and Drug Administration approved Yesafili in May 2024 and granted it interchangeable designation for the vial formulation, allowing pharmacy-level substitution in accordance with state laws. The pre-filled syringe carries provisional interchangeability status.</p> <p>Yesafili is indicated for neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. The FDA approval was based on analytical, nonclinical, and clinical data, including a Phase 3 http://www.streetinsider.com/Corporate+News/Biocon+launches+Yesafili%2C+a+biosimilar+to+Eylea+2+mg%2C+in+the+U.S./26853770.html Mon, 03 Aug 2026 07:05:15 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Press+Releases/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html <ul class="bwlistdisc"> <li> Yesafili™<b> </b>(aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg </li> <li> Potential benefit to the ~20 million adults in the U.S. with age-related macular degeneration and other serious eye conditions </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the commercial launch of <b>Yesafili™ (aflibercept-jbvf)</b> in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept) 2 mg. The product was approved previously http://www.streetinsider.com/Press+Releases/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html Mon, 03 Aug 2026 07:05:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Press+Releases/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html <ul class="bwlistdisc"> <li> Yesafili™<b> </b>(aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg </li> <li> Potential benefit to the ~20 million adults in the U.S. with age-related macular degeneration and other serious eye conditions </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the commercial launch of <b>Yesafili™ (aflibercept-jbvf)</b> in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept) 2 mg. The product was approved previously http://www.streetinsider.com/Press+Releases/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html Mon, 03 Aug 2026 07:05:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Press+Releases/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html <ul class="bwlistdisc"> <li> Yesafili™<b> </b>(aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg </li> <li> Potential benefit to the ~20 million adults in the U.S. with age-related macular degeneration and other serious eye conditions </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the commercial launch of <b>Yesafili™ (aflibercept-jbvf)</b> in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept) 2 mg. The product was approved previously http://www.streetinsider.com/Press+Releases/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html Mon, 03 Aug 2026 07:05:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Press+Releases/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html <ul class="bwlistdisc"> <li> Yesafili™<b> </b>(aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg </li> <li> Potential benefit to the ~20 million adults in the U.S. with age-related macular degeneration and other serious eye conditions </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the commercial launch of <b>Yesafili™ (aflibercept-jbvf)</b> in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept) 2 mg. The product was approved previously http://www.streetinsider.com/Press+Releases/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html Mon, 03 Aug 2026 07:05:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Press+Releases/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html <ul class="bwlistdisc"> <li> Yesafili™<b> </b>(aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg </li> <li> Potential benefit to the ~20 million adults in the U.S. with age-related macular degeneration and other serious eye conditions </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the commercial launch of <b>Yesafili™ (aflibercept-jbvf)</b> in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept) 2 mg. The product was approved previously http://www.streetinsider.com/Press+Releases/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html Mon, 03 Aug 2026 07:05:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Business+Wire/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html <ul class="bwlistdisc"> <li> Yesafili™<b> </b>(aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg </li> <li> Potential benefit to the ~20 million adults in the U.S. with age-related macular degeneration and other serious eye conditions </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the commercial launch of <b>Yesafili™ (aflibercept-jbvf)</b> in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept) 2 mg. The product was approved previously http://www.streetinsider.com/Business+Wire/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html Mon, 03 Aug 2026 07:05:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Business+Wire/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html <ul class="bwlistdisc"> <li> Yesafili™<b> </b>(aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg </li> <li> Potential benefit to the ~20 million adults in the U.S. with age-related macular degeneration and other serious eye conditions </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the commercial launch of <b>Yesafili™ (aflibercept-jbvf)</b> in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept) 2 mg. The product was approved previously http://www.streetinsider.com/Business+Wire/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html Mon, 03 Aug 2026 07:05:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Business+Wire/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html <ul class="bwlistdisc"> <li> Yesafili™<b> </b>(aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg </li> <li> Potential benefit to the ~20 million adults in the U.S. with age-related macular degeneration and other serious eye conditions </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the commercial launch of <b>Yesafili™ (aflibercept-jbvf)</b> in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept) 2 mg. The product was approved previously http://www.streetinsider.com/Business+Wire/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html Mon, 03 Aug 2026 07:05:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Business+Wire/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html <ul class="bwlistdisc"> <li> Yesafili™<b> </b>(aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg </li> <li> Potential benefit to the ~20 million adults in the U.S. with age-related macular degeneration and other serious eye conditions </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the commercial launch of <b>Yesafili™ (aflibercept-jbvf)</b> in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept) 2 mg. The product was approved previously http://www.streetinsider.com/Business+Wire/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html Mon, 03 Aug 2026 07:05:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Business+Wire/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html <ul class="bwlistdisc"> <li> Yesafili™<b> </b>(aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg </li> <li> Potential benefit to the ~20 million adults in the U.S. with age-related macular degeneration and other serious eye conditions </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the commercial launch of <b>Yesafili™ (aflibercept-jbvf)</b> in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept) 2 mg. The product was approved previously http://www.streetinsider.com/Business+Wire/Biocon+Announces+U.S.+Commercial+Launch+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Regeneron%E2%80%99s+Eylea%C2%AE+2+mg/26853763.html Mon, 03 Aug 2026 07:05:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Press+Releases/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html <ul class="bwlistdisc"> <li> <b>Key findings published in the <i>British Journal of Ophthalmology</i>: </b>Patients who continued on MYL‑1701P and those who switched from reference aflibercept to MYL‑1701P showed <b>similar safety, efficacy, and immunogenicity outcomes through the 20</b>‑<b>week extension</b>, with maintained visual and anatomic results. </li> <li> <b>Key findings published in <i>Expert Opinion on Biological Therapy</i>: </b>Across clinically relevant patient subgroups, MYL‑1701P demonstrated <b>comparable improvements in visual acuity and retinal thickness to reference aflibercept</b>, supporting clinical equivalence across diverse DME populations. </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the publication of two important http://www.streetinsider.com/Press+Releases/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html Thu, 09 Jul 2026 07:35:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Press+Releases/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html <ul class="bwlistdisc"> <li> <b>Key findings published in the <i>British Journal of Ophthalmology</i>: </b>Patients who continued on MYL‑1701P and those who switched from reference aflibercept to MYL‑1701P showed <b>similar safety, efficacy, and immunogenicity outcomes through the 20</b>‑<b>week extension</b>, with maintained visual and anatomic results. </li> <li> <b>Key findings published in <i>Expert Opinion on Biological Therapy</i>: </b>Across clinically relevant patient subgroups, MYL‑1701P demonstrated <b>comparable improvements in visual acuity and retinal thickness to reference aflibercept</b>, supporting clinical equivalence across diverse DME populations. </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the publication of two important http://www.streetinsider.com/Press+Releases/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html Thu, 09 Jul 2026 07:35:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Press+Releases/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html <ul class="bwlistdisc"> <li> <b>Key findings published in the <i>British Journal of Ophthalmology</i>: </b>Patients who continued on MYL‑1701P and those who switched from reference aflibercept to MYL‑1701P showed <b>similar safety, efficacy, and immunogenicity outcomes through the 20</b>‑<b>week extension</b>, with maintained visual and anatomic results. </li> <li> <b>Key findings published in <i>Expert Opinion on Biological Therapy</i>: </b>Across clinically relevant patient subgroups, MYL‑1701P demonstrated <b>comparable improvements in visual acuity and retinal thickness to reference aflibercept</b>, supporting clinical equivalence across diverse DME populations. </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the publication of two important http://www.streetinsider.com/Press+Releases/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html Thu, 09 Jul 2026 07:35:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Press+Releases/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html <ul class="bwlistdisc"> <li> <b>Key findings published in the <i>British Journal of Ophthalmology</i>: </b>Patients who continued on MYL‑1701P and those who switched from reference aflibercept to MYL‑1701P showed <b>similar safety, efficacy, and immunogenicity outcomes through the 20</b>‑<b>week extension</b>, with maintained visual and anatomic results. </li> <li> <b>Key findings published in <i>Expert Opinion on Biological Therapy</i>: </b>Across clinically relevant patient subgroups, MYL‑1701P demonstrated <b>comparable improvements in visual acuity and retinal thickness to reference aflibercept</b>, supporting clinical equivalence across diverse DME populations. </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the publication of two important http://www.streetinsider.com/Press+Releases/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html Thu, 09 Jul 2026 07:35:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Press+Releases/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html <ul class="bwlistdisc"> <li> <b>Key findings published in the <i>British Journal of Ophthalmology</i>: </b>Patients who continued on MYL‑1701P and those who switched from reference aflibercept to MYL‑1701P showed <b>similar safety, efficacy, and immunogenicity outcomes through the 20</b>‑<b>week extension</b>, with maintained visual and anatomic results. </li> <li> <b>Key findings published in <i>Expert Opinion on Biological Therapy</i>: </b>Across clinically relevant patient subgroups, MYL‑1701P demonstrated <b>comparable improvements in visual acuity and retinal thickness to reference aflibercept</b>, supporting clinical equivalence across diverse DME populations. </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the publication of two important http://www.streetinsider.com/Press+Releases/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html Thu, 09 Jul 2026 07:35:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Business+Wire/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html <ul class="bwlistdisc"> <li> <b>Key findings published in the <i>British Journal of Ophthalmology</i>: </b>Patients who continued on MYL‑1701P and those who switched from reference aflibercept to MYL‑1701P showed <b>similar safety, efficacy, and immunogenicity outcomes through the 20</b>‑<b>week extension</b>, with maintained visual and anatomic results. </li> <li> <b>Key findings published in <i>Expert Opinion on Biological Therapy</i>: </b>Across clinically relevant patient subgroups, MYL‑1701P demonstrated <b>comparable improvements in visual acuity and retinal thickness to reference aflibercept</b>, supporting clinical equivalence across diverse DME populations. </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the publication of two important http://www.streetinsider.com/Business+Wire/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html Thu, 09 Jul 2026 07:35:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Business+Wire/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html <ul class="bwlistdisc"> <li> <b>Key findings published in the <i>British Journal of Ophthalmology</i>: </b>Patients who continued on MYL‑1701P and those who switched from reference aflibercept to MYL‑1701P showed <b>similar safety, efficacy, and immunogenicity outcomes through the 20</b>‑<b>week extension</b>, with maintained visual and anatomic results. </li> <li> <b>Key findings published in <i>Expert Opinion on Biological Therapy</i>: </b>Across clinically relevant patient subgroups, MYL‑1701P demonstrated <b>comparable improvements in visual acuity and retinal thickness to reference aflibercept</b>, supporting clinical equivalence across diverse DME populations. </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the publication of two important http://www.streetinsider.com/Business+Wire/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html Thu, 09 Jul 2026 07:35:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Business+Wire/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html <ul class="bwlistdisc"> <li> <b>Key findings published in the <i>British Journal of Ophthalmology</i>: </b>Patients who continued on MYL‑1701P and those who switched from reference aflibercept to MYL‑1701P showed <b>similar safety, efficacy, and immunogenicity outcomes through the 20</b>‑<b>week extension</b>, with maintained visual and anatomic results. </li> <li> <b>Key findings published in <i>Expert Opinion on Biological Therapy</i>: </b>Across clinically relevant patient subgroups, MYL‑1701P demonstrated <b>comparable improvements in visual acuity and retinal thickness to reference aflibercept</b>, supporting clinical equivalence across diverse DME populations. </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the publication of two important http://www.streetinsider.com/Business+Wire/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html Thu, 09 Jul 2026 07:35:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Business+Wire/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html <ul class="bwlistdisc"> <li> <b>Key findings published in the <i>British Journal of Ophthalmology</i>: </b>Patients who continued on MYL‑1701P and those who switched from reference aflibercept to MYL‑1701P showed <b>similar safety, efficacy, and immunogenicity outcomes through the 20</b>‑<b>week extension</b>, with maintained visual and anatomic results. </li> <li> <b>Key findings published in <i>Expert Opinion on Biological Therapy</i>: </b>Across clinically relevant patient subgroups, MYL‑1701P demonstrated <b>comparable improvements in visual acuity and retinal thickness to reference aflibercept</b>, supporting clinical equivalence across diverse DME populations. </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the publication of two important http://www.streetinsider.com/Business+Wire/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html Thu, 09 Jul 2026 07:35:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344 http://www.streetinsider.com/Business+Wire/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html <ul class="bwlistdisc"> <li> <b>Key findings published in the <i>British Journal of Ophthalmology</i>: </b>Patients who continued on MYL‑1701P and those who switched from reference aflibercept to MYL‑1701P showed <b>similar safety, efficacy, and immunogenicity outcomes through the 20</b>‑<b>week extension</b>, with maintained visual and anatomic results. </li> <li> <b>Key findings published in <i>Expert Opinion on Biological Therapy</i>: </b>Across clinically relevant patient subgroups, MYL‑1701P demonstrated <b>comparable improvements in visual acuity and retinal thickness to reference aflibercept</b>, supporting clinical equivalence across diverse DME populations. </li> </ul> <p> BENGALURU, India &amp; BRIDGEWATER, N.J.--(BUSINESS WIRE)-- <b>Biocon Limited (BSE: 532523; NSE: BIOCON), </b>an innovation‑led global biopharmaceutical company, today announced the publication of two important http://www.streetinsider.com/Business+Wire/Biocon+Announces+Publication+of+Pivotal+Clinical+Data+Supporting+Effectiveness+of+Yesafili%E2%84%A2%2C+a+Biosimilar+to+Eylea%C2%AE+%28Aflibercept%29/26750150.html Thu, 09 Jul 2026 07:35:00 -0400 532523 A.06822034 BIOCON O.01260902 O.20026344